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Abstract
Objective: The contribution of depression to mortality in adults with and without HIV is unclear. 
We hypothesized that depression increases mortality risk and this association is stronger among 
those with HIV.
Methods: Veterans Aging Cohort Study (VACS) data were analyzed from the first clinic visit on/
after 4/1/2003 (baseline) to 9/30/2015. Depression definitions: 1) major depressive disorder by 
ICD-9 codes; 2) depressive symptoms by Patient Health Questionnaire (PHQ)-9 scores ≥ 10. 
Outcome: all-cause mortality. Covariates: demographics, comorbid conditions, health behaviors.
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Results: Among 129,140 eligible participants, 30% had HIV, 16% had major depressive disorder 
diagnosis, and 24% died over a median follow-up of 11 years. The death rate (95% confidence 
interval [CI]) was 25.3 [25.0–25.6] deaths per 1000 person-years. Major depressive disorder was 
associated with mortality: hazard ratio (HR) [95% CI] = 1.04 [1.01, 1.07]. This association was 
modified by HIV status (interaction p-value=0.02). In HIV-stratified analyses, depression was 
significantly associated with mortality among HIV uninfected veterans but not among those with 
HIV. Among those with PHQ-9 data (N=7372), 50% had HIV, 22% had PHQ-9 scores ≥ 10, and 
28% died over a median follow-up of 12 years. The death rate was 27.3 (26.1–28.5) per 1000 
person-years. Depressive symptoms were associated with mortality (1.16 [1.04, 1.28]). This 
association was modified by HIV status (interaction p-value=0.05). In HIV-stratified analyses, 
depressive symptoms were significantly associated with mortality among veterans with HIV but 
not among those without HIV.
Conclusion: Depression was associated with all-cause mortality. This association was modified 
by HIV status and method of depression ascertainment.
Keywords
HIV; depression; mortality
Introduction
Depression is the most frequently reported mental health condition in people living with 
HIV in the United States (U.S.), with prevalence ranging from 20–40%.(1–5) Depressive 
disorders have been associated with increased mortality in persons with chronic diseases, 
including heart disease, end stage renal disease, and diabetes.(6–8) Several studies have 
described similar associations in the context of HIV infection, although conflicting data 
exist. Limitations in prior work include absence of a comparator group without HIV that 
would inform conclusions about whether HIV infection modifies the association between 
depression and mortality. If HIV infection strengthens the association between depression 
and mortality, this would suggest that among people with HIV, greater emphasis on 
depression screening, better synchronization of HIV and depression treatment, and more 
research into the mechanisms underlying the interaction of HIV and depression on mortality 
risk are warranted. Thus, it is important to understand the interplay among HIV infection, 
depression and all-cause mortality (Figure 1). Our objectives were to assess the independent 
association of depression and mortality and to determine whether and how HIV modifies this 
association.
Methods
Study design and participants
We used the Veterans Aging Cohort Study (VACS) to assess the relationships between 
depression, HIV infection, and all-cause mortality. The VACS is a prospective, multisite, 
longitudinal cohort of HIV-infected and age, race/ethnicity, and geographic region matched 
uninfected adults in the U.S. Department of Veterans Affairs (VA) system.(9) In the VACS 
each HIV-infected veteran is matched to two uninfected veterans also in clinical care. The 
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baseline date of participation was defined as the date of a participant’s first clinic visit on or 
after April 1, 2003.
A subset of VACS participants completed comprehensive annual health and behavior 
surveys. These surveys included the PHQ-9, a validated screening tool for major depressive 
disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th 
Edition (DSM-IV) criteria.(10) For this subset of participants (PHQ-9 subset), an additional 
baseline was defined as the date on which they completed their baseline survey. This was to 
enable analyses using two different definitions for depression status i.e. diagnostic codes and 
formal depression screening.
All participants were followed from their baseline date until date of death, the last follow-up 
date, or the censoring date of February 11, 2016.
The University of Pittsburgh, Yale University, and West Haven VA Medical Center 
institutional review boards approved this study.
Outcome variable
The primary outcome variable was all-cause mortality, which was determined from the VA 
vital status file, the Social Security Administration death master file, the Beneficiary 
Identification and Records Locator Subsystem, and the Veterans Health Administration 
Medical Statistical Analysis Systems inpatient data sets.
Exposure variables
The primary exposure variable was depression. We defined depression at baseline as having 
at least one inpatient or two outpatient International Classification of Diseases, Ninth 
Revision [ICD-9] codes for major depressive disorder (296.2 or 296.3).(11, 12) Among 
those with PHQ-9 data available at baseline (PHQ-9 subset), we also defined clinically 
significant depressive symptoms as a PHQ-9 score ≥ 10.(13) PHQ-9 scores ≥ 10 indicate the 
presence of depressive symptoms with strong reliability and validity for diagnosing major 
depressive disorder.(14)
Effect modifier and covariates
HIV status was the primary effect modifier. HIV infection was defined as at least one 
inpatient or two outpatient ICD-9 codes for HIV in the VA Immunology Case Registry as 
previously described.(15)
HIV-specific data included in these analyses were CD4 cell count, HIV-1 RNA level, and 
antiretroviral therapy (ART) regimen obtained as part of clinical care at baseline (defined as 
180 days prior to through 7 days after the baseline enrollment date). Baseline CD4 cell 
counts were categorized as ≥500/mm3, 200–499/mm3, or <200/mm3 and HIV-1 RNA levels 
as <500 or ≥500 copies/mL. Being on any ART regimen (yes/no) and the use of efavirenz 
(which was specifically included due to its potential neuropsychiatric effects and higher risk 
of suicidality(16)), were obtained through pharmacy data.
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Covariates were obtained closest to baseline date as previously described.(17, 18) 
Sociodemographic variables of age, self-reported sex, and self-reported race/ethnicity were 
determined through administrative data. History of cardiovascular disease, chronic 
obstructive pulmonary disease, and cancer (either AIDS-defining or non-AIDS-defining) 
were assessed by ICD-9 codes as previously defined.(19–24) History of an AIDS-defining 
illness was also defined by ICD-9 codes (Supplementary Table 1). Systolic blood pressure 
(SBP) and diastolic blood pressure (DBP) were defined by averaging the three routine 
outpatient systolic and diastolic blood pressure measurements performed closest to the 
baseline date. Hypertension was categorized as no hypertension (blood pressure 
<140/90mmHg and no antihypertensive medication), controlled hypertension (<140/90 
mmHg with antihypertensive medication), or uncontrolled hypertension (≥140/90 mmHg). 
GFR was estimated using the CKD-EPI equation(25) and was categorized as <60 or ≥60 
mL/min/1.73m2. Hemoglobin levels were categorized as either <12g/dL or ≥12g/dL. 
Diabetes was identified using a previously validated metric that incorporates glucose 
measurements, antidiabetic agent use, and/or at least one inpatient or two outpatient ICD-9 
codes for diabetes.(26) Hepatitis C virus seropositivity was defined as a positive hepatitis C 
virus antibody test result or at least one inpatient or two outpatient ICD-9 codes for this 
diagnosis.(27)
Smoking and body mass index (BMI, calculated as weight in kilograms divided by height in 
meters squared) were assessed using the VA electronic medical record health factor data 
collected through standardized clinical reminders to VA clinicians.(28) Smoking was 
categorized as never, current, or past, and BMI was dichotomously categorized (<30 or ≥30 
kg/m2). History of alcohol abuse or dependence and history of cocaine use were defined 
using ICD-9 codes.(29)
For analyses restricted to the PHQ-9 subset, smoking data were from self-report, BMI data 
were from laboratory results, alcohol use data were from both Alcohol Use Disorders 
Identification Test (AUDIT-C) and ICD-9 codes (28, 30). For analysis using AUDIT-C data, 
alcohol use was categorized as not current, not hazardous, hazardous, at-risk or heavy 
episodic, or alcohol abuse or dependence.
Baseline antidepressant use was assessed using VA pharmacy records documenting a filled 
prescription for the following selective serotonin reuptake inhibitors: citalopram, 
escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline; and tricyclic 
antidepressants: amitriptyline, amitriptyline/perphenazine, clomipramine, desipramine, 
doxepin, imipramine, and nortriptyline. ICD-9 codes were used to define schizophrenia, 
bipolar disorder, and post-traumatic stress disorder (PTSD) (Supplementary Table 1).
Statistical Analysis
Baseline characteristics were stratified by depression status and presented as median 
(interquartile range) for continuous variables and frequencies with percentages for 
categorical variables.
Cox proportional hazards models were used to estimate the association of depression status 
with all-cause mortality. We applied restricted cubic splines on continuous predictors in 
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order to allow a nonlinear relationship between the covariate and outcome. Interactions 
between depression and HIV status were assessed in each model. The proportional hazards 
assumption was tested by the Schoenfeld residuals and including the interaction term of the 
covariates by time as evaluated by the “cox.zph” function in R. We also constructed Kaplan-
Meier curves showing survival distributions over follow-up time.
We constructed three Cox models to estimate the association of depressive disorder 
diagnoses or depression symptoms, defined using either ICD-9 codes or PHQ-9 scores 
respectively, and mortality. Model 1 was adjusted for HIV status. Model 2 adjusted for 
demographics (age, sex, race/ethnicity) and HIV status. Model 3 built upon Model 2 and 
additionally adjusted for co-morbid conditions that could confound the association between 
depression and mortality including prevalent cardiovascular disease, AIDS-defining 
illnesses, chronic obstructive pulmonary disease, cancer, diabetes, hypertension, 
hypercholesterolemia, renal disease, anemia and hepatitis C seropositivity. Model 3 was our 
primary model. Model 3B included an interaction term for depression and HIV status. 
Interactions were considered statistically significant at the p<0.10 threshold and HIV-
stratified analyses were performed. HIV-stratified analyses were further adjusted for HIV-1 
RNA, CD4+ T-cell count and antiretroviral therapy prescription among those with HIV.
We then performed several exploratory analyses to assess the effects of other potential 
confounding or mediating influences on the relationships between depression and all-cause 
mortality. First, we added behavioral factors including baseline body mass index (a surrogate 
of diet and physical activity), smoking status, alcohol use, and cocaine use to Model 3. Then, 
we adjusted Model 3 for other mental health diagnoses present at baseline, i.e., 
schizophrenia, bipolar disorder, and post-traumatic stress disorder. Lastly, we examined the 
role of antidepressant medication use by adjusting Model 3 for use of selective serotonin 
reuptake inhibitor or tricyclic antidepressant medications prescribed at baseline.
Missing data methods are described in the Online Supplement.
Results
Characteristics of the VACS participants
There were 129,140 VACS participants included in this study with a mean age of 50 years, 
>90% men, 50% black or African American, and median (IQR) duration of follow-up was 
10.7 (6.3–12.7) years (Table 1). Of these participants, 16% had a diagnosis of major 
depressive disorder at baseline. Among those with major depressive disorder, 32% had HIV 
compared to an HIV prevalence of 30% among those without major depressive disorder. 
Those with major depressive disorder had a higher prevalence of cardiovascular disease, 
chronic obstructive pulmonary disease, hepatitis C, current smoking, alcohol or cocaine 
abuse/dependence diagnoses, and history of schizophrenia, bipolar disorder, or post-
traumatic stress disorder (Table 1). These characteristics were similar in the PHQ-9 subset 
(median (IQR) follow-up time 12.2 (7.4–13.0) years) with the exception of prevalent 
cardiovascular disease, which had similar prevalence among those with PHQ-9< 10 
compared to those with PHQ-9≥10.
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Unadjusted mortality rates
At the end of follow-up, almost 24% of the VACS cohort had died, giving a mortality rate of 
25 deaths per 1000 person years. Among HIV uninfected people, mortality rates (95% 
confidence interval) were 20.2 (19.9–20.5) among those without major depressive disorder 
and 22.7 (21.0–23.5) among those with major depressive disorder. Among those with HIV, 
these rates were 36.9 (36.2–37.7) and 39.4 (37.8–41.0), respectively (Table 2). In the PHQ-9 
subset, mortality rates were similar among uninfected people with PHQ-9 score <10 
compared to their counterparts with PHQ-9 score ≥10. However, mortality rates were higher 
among those with HIV with PHQ-9≥10 (43.2 [38.6–48.1]) versus PHQ-9<10 (33.7 [31.6–
36.0]) (Table 2).
Associations between depression and mortality
A diagnosis of major depressive disorder was associated with a 9% increased risk of 
mortality adjusting for HIV status only (Table 3a). This association persisted after further 
adjustment for demographics and comorbid conditions that could confound the association 
between major depressive disorder and mortality (Table 3a). The hazard ratio (95% 
confidence interval) for major depressive disorder in the primary model (Model 3a) was 1.04 
(1.01–1.07). We detected a significant interaction between major depressive disorder and 
HIV status (p=0.02). Thus, we stratified our analyses by HIV status and detected modestly 
increased mortality risk associated with major depressive disorder that reached statistical 
significance among HIV uninfected people (1.06 [1.02–1.11]) but not among people with 
HIV (1.04 [0.99–1.09]; Table 3b). Exploratory analyses adjusting for behavioral factors, 
mental health diagnoses, and depression treatment completely attenuated the modest 
associations observed in the primary analyses regardless of HIV status (Table 4a).
In the PHQ-9 subset, compared to those with PHQ-9<10, veterans with PHQ-9≥10 had a 
17% increased risk of mortality adjusting for HIV status only (Table 4a). This association 
persisted in fully adjusted models (Table 4a). The hazard ratio (95% confidence interval) 
PHQ-9≥10 in the primary model was 1.16 (1.04–1.28). We detected a significant interaction 
between depressive symptoms and HIV status (p=0.05). Thus, we stratified our analyses by 
HIV status and detected no increased mortality risk associated with PHQ-9≥10 among HIV 
uninfected people (1.00 [0.83–1.20]) but significantly increased mortality risk associated 
with PHQ-9≥10 among people with HIV (1.24 [1.09–1.42]; Table 4b). Exploratory analyses 
adjusting for behavioral factors, mental health diagnoses, and depression treatment had little 
impact on the associations observed in the primary analyses (Table 4b).
Discussion
To our knowledge, this is the largest cohort study to date investigating the relationships 
among depressive disorders or symptoms, HIV status, and all-cause mortality. We report a 
moderate association of depressive symptoms and a modest association of depression 
diagnoses with mortality, which appear to differ by HIV status. Among people with HIV, 
there was a 24% increased mortality risk associated with elevated depressive symptoms 
ascertained by PHQ-9 but no significant increase in risk for depressive disorders ascertained 
by ICD-9 codes. For HIV uninfected people, there was a 6% increased mortlity risk 
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associated with depressive disorders ascertained by ICD-9 codes and a non-significant 4% 
increased mortality risk for elevated depressive symptoms ascertained by PHQ-9.
Prior studies investigating depression and mortality among people with HIV have reported 
increased mortality risk among those with depression diagnoses or questionnaire-based 
depressive symptoms (2, 31–37) with exceptions.(1, 38) Some studies have focused on 
multiple mental health and/or substance use disorders (39), while others investigated joint 
effects of depression and antiretroviral therapy adherance on mortality.(40, 41) None of 
these studies included a group of people without HIV to determine whether HIV status 
modifies the effect of depression on mortality. The current study therefore extends the 
existing literature with the finding of an associaiton of depressive symptoms with mortality 
among people with HIV but not among HIV uninfected people.
The discrepancy in our findings between depression diagnoses (ICD-9) and depressive 
symptoms (PHQ-9) may have multiple explanations. First, it may reflect a positive effect of 
depression treatment on mortality risk. If people with a clinical diagnosis are more likely to 
receive treatment for – and thus improvement in – their depression than people with 
depressive symptoms without a clinical diagnosis, this would explain why depressive 
symptoms but not depression diagnoses were associated with mortality among people with 
HIV. Second, it may reflect lower risk of depression missclassification in the PHQ-9 subset 
versus the full VACS cohort. This is because the PHQ-9 was administered to everyone in the 
PHQ-9 subset (i.e., systematic assessment), reducing the likelihood of depression 
misclassification compared to ICD-9 codes recorded as part of routine clinical care (i.e. non-
systematic assessment). Additionally, most of the above-referenced HIV studies used 
questionnaires to measure depressive symptoms and reported associations of depressive 
symptoms and mortality consistent with our findings among those with HIV. The two studies 
investigating major depressive disorder diagnoses (ICD-9 codes) and mortality among 
people with HIV reported conflicting results. The first (also from the VA) found no 
association of depressive disorders with mortality (1) while the second (from Kaiser 
Permanente Northern California) found psychiatric diagnoses (including major depressive 
disorder) were associated with increased mortality risk.(39) Our results are consistent with 
the other VA study and difficult to compare to the Kaiser Permanente study, which did not 
specifically report associations for major depressive disorders alone.
Analyses in most of the prior HIV studies had limited adjustment for potential confounders 
beyond demographics, HIV, HIV treatment and immune function characteristics. Our 
primary analysis included demographics, cardiovascular and pulmonary diseases, cancer, 
diabetes, and hepatitis C. These comorbidities are known to be associated with both 
depression and mortality,(42–47) and, as such, need to be adjusted for as potential 
confounders. Although several previous meta-analyses(48–50) in the general population 
have reported a positive association between depression and mortality, few of the included 
studies accounted for potential confounders beyond demographics and calendar time. For 
example, in a 2015 meta-analysis of 203 studies of mortality in mental disorders in the 
general population, seven adjusted for smoking and two adjusted for diabetes.(50) Thus, our 
results extend the literature by providing effect sizes that may be more reflective of the 
independent effect of depression on mortality among HIV uninfected people.
So-Armah et al. Page 8
HIV Med. Author manuscript; available in PMC 2020 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Although our study was not designed to assess the mechanisms by which HIV infection 
modifies the association between depressive symptoms and mortality, we offer potential 
explanations for this result. It is possible that AIDS-related mortality drives a substantial 
proportion of the association between depression and mortality among those with HIV. This 
idea is supported by prior work supporting a positive associations between depression and 
AIDS-related mortality and no association between depressive symptoms and mortality 
among people initiating antiretroviral therapy who were adherent to this therapy.(1, 34, 36, 
37, 40, 41) Second, HIV infection is associated with other detrimental behaviors (e.g., 
substance misuse, polypharmcy leading to reduced treatment adherence, social isolation),
(51–53) which could feedback to depression symptom recurrence or exacerbation and 
amplify the association of depression with mortality (Figure 1). A third potential explanation 
involves the association of both HIV infection and depression with increased chronic 
systemic inflammation, (17, 54, 55) an immunologic phenomenon associated with increased 
mortality risk.(56–58) In this case, we speculate that combined effect of chronic systemic 
inflammation from both HIV and depression on mortality is greater than would have been 
expected from their individual effects.(59).
If HIV infection increases the risk of death associated with depressive symptoms, this has 
important clinical and research implications. As people with HIV are living longer, their risk 
for diseases of aging (e.g., cancer, cardiovascular disease) increases, and this risk is 
accentuated (higher risk at all ages) among people with HIV compared to those without HIV 
infection.(60) These diseases of aging are associated with depression and may, combined 
with HIV, further increase mortality risk in this population (i.e., three-way interaction 
between HIV, depression and diseases of aging). Despite clinical guidelines recommending 
routine screening for depressive symptoms, there is varying success in implementation and 
there is underdiagnosis of depression in HIV.(61–63) This needs to be improved; better 
understanding of barriers and facilitators to effective depression screening and integrating 
depression treatment into HIV primary care is needed. Even with effective screening, 
depression treatment is challenging,(64) particularly in the context of HIV infection. Many 
people with HIV in the combination antiretroviral therapy era are on at least five 
medications.(65) Adding depression therapy to this background increases risk of harm from 
polypharmacy including drug drug interactions and decreased treatment adherence. To 
reduce mortality risk associated with depression among people with HIV, future studies 
compare watchful waiting, pharmacotherapy, psychotherapy and their appropriate 
combination paying close attention to the adverse effects of polypharmacy.
There were limitations to this analysis. First, we did not perform time-updated analyses. 
This may have led to an underestimation of effects depression on mortality because new 
onset depression was not captured. Second, these results may not be generalizable to 
women. Third, we cannot exclude the possibility that even with our extensive adjustments, 
unmeasured confounding due to other variables differing between the HIV and depressed 
subgroups led to discordant results.
In conclusion, we found that depressive symptoms were moderately associated with all-
cause mortality among U.S. veterans with HIV but not among their counterparts without 
HIV infection. Depression diagnoses were modestly associated with mortality among those 
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without HIV but not among those with HIV infection. To reduce mortality risk, these 
findings reinforce the need to assess and treat depressive symptoms and major depressive 
disorder in patients with and without HIV infection; a strategy supported by a recently 
published trial showing depression treatment is associated with long-term cardiac outcomes 
(including mortality) among people with recent acute coronary syndrome.(66) Particularly 
among people with HIV, there is a need to compare the effectiveness of different depression 
treatment modalities (e.g., watchful waiting, pharmacotherpy, psychotherapy) accounting for 
health consequences of polypharmacy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Key points:
Depressive symptoms were associated with all-cause mortality among those with HIV 
but not among their counterparts without HIV infection. Depression diagnoses were 
modestly associated with mortality among those without HIV but not among those with 
HIV infection.
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Research in context
Evidence before this study:
Depressive disorders have been associated with increased mortality in persons with 
chronic diseases, including heart disease, end stage renal disease, and diabetes. Several 
studies have described similar associations in the context of HIV infection, although 
conflicting data exist. Limitations in prior work include absence of a comparator group 
without HIV that would inform conclusions about whether HIV infection modifies the 
association between depression and mortality.
Added value of this study:
This is the largest cohort study to date investigating the relationships among depressive 
disorders or symptoms, HIV status (including HIV uninfected comparators), and all-
cause mortality.
Implications of available evidence:
To reduce mortality risk, our findings reinforce the need to assess and treat depressive 
symptoms and major depressive disorder in patients with and without HIV infection.
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Figure 1. 
Conceptual model linking depression and mortality and highlighting a potential role for HIV 
as an effect modifier.
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Table 3b:
HIV-stratified mortality risk by diagnosis of major depressive disorder (defined by ICD-9 code) in the Veterans 
Aging Cohort Study (VACS)
Hazard ratio [95% CI]
HIV uninfected HIV infected
Model 3
No major depressive disorder 1 (ref) 1 (ref)
Major depressive disorder 1.06 (1.02, 1.11) 1.04 (0.99, 1.09)
Model 4
No major depressive disorder 1 (ref) 1 (ref)
Major depressive disorder 0.98 (0.94, 1.02) 0.99 (0.95, 1.04)
Model 5
No major depressive disorder 1 (ref) 1 (ref)
Major depressive disorder 1.02 (0.98, 1.07) 1.01 (0.96, 1.06)
Model 6
No major depressive disorder 1 (ref) 1 (ref)
Major depressive disorder 1.01 (0.96, 1.05) 0.97 (0.92, 1.02)
Model 3 adjusted age, sex, race, prevalent cardiovascular disease, chronic obstructive pulmonary disease, cancer, diabetes, systolic blood pressure, 
diastolic blood pressure, total cholesterol, estimated glomerular filtration rate, hemoglobin, and hepatitis C seropositivity. Model 4 adjusted for 3 
for body mass index, smoking status, alcohol use, cocaine use. Model 5 adjusted Model 3 for baseline diagnosis of schizophrenia, bipolar disorder, 
and post-traumatic stress disorder. Model 6 adjusted Model 3 for baseline prescription of selective serotonin reuptake inhibitors and tricyclic 
antidepressant medications. All Models for the HIV-infected participants were then further adjusted for baseline use of antiretroviral therapy, CD4 
cell count, and HIV-1 RNA level
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Table 4b:
HIV-stratified mortality risk by depressive symptoms (defined by PHQ-9) in the PHQ-9 subset
Hazard ratio [95% CI]
HIV uninfected HIV infected
Model 3
No moderate/severe depression by PHQ-9 1 (ref) 1 (ref)
Moderate or severe depression by PHQ-9 1.00 (0.83, 1.20) 1.23 (1.08, 1.41)
Model 4
No moderate/severe depression by PHQ-9 1 (ref) 1 (ref)
Moderate or severe depression by PHQ-9 0.89 (0.74, 1.07) 1.17 (1.02, 1.33)
Model 5
No moderate/severe depression by PHQ-9 1 (ref) 1 (ref)
Moderate or severe depression by PHQ-9 0.98 (0.81, 1.18) 1.22 (1.07, 1.39)
Model 6
No moderate/severe depression by PHQ-9 1 (ref) 1 (ref)
Moderate or severe depression by PHQ-9 0.96 (0.80, 1.16) 1.22 (1.07, 1.40)
Model 3 adjusted age, sex, race, prevalent cardiovascular disease, chronic obstructive pulmonary disease, cancer, diabetes, systolic blood pressure, 
diastolic blood pressure, total cholesterol, estimated glomerular filtration rate, hemoglobin, and hepatitis C seropositivity. Model 4 adjusted for 3 
for body mass index, smoking status, alcohol use, cocaine use. Model 5 adjusted Model 3 for baseline diagnosis of schizophrenia, bipolar disorder, 
and post-traumatic stress disorder. Model 6 adjusted Model 3 for baseline prescription of selective serotonin reuptake inhibitors and tricyclic 
antidepressant medications. All Models for the HIV-infected participants were then further adjusted for baseline use of antiretroviral therapy, CD4 
cell count, and HIV-1 RNA level.
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